Conceptual image of the new R&D facility
Denka Company Limited (headquarters: Chuo-ku, Tokyo; president: Manabu Yamamoto; hereinafter, “Denka”) announces that Icon Genetics GmbH (hereinafter, ”Icon Genetics”), a fully owned subsidiary of Denka, concluded a land purchase agreement with the city of Halle, Sachsen-Anhalt in Germany on March 11, 2020. The land will be used for the construction of a new facility as part of Denka’s healthcare business enhancement.
Denka currently supports Icon Genetics’ development of a norovirus vaccine candidate and the manufacturing of proteins for diagnostic use. These programs are enabled by Icon Genetics’ proprietary, plant-based magnICON® platform technology. To satisfy the need for expansion of Icon Genetics’ capacity, Denka is purchasing approximately 50,000 m2 of land to build a pilot plant in the Weinberg Campus Technological Park in Halle, near Icon Genetics’ current facility. The new facility will serve as the center for Icon Genetics’ research, development and production activities.
Denka positioned its healthcare-related businesses as one of the three priority fields in the Denka Value-Up Management Plan and is consolidating management resources in this field. Through this investment, Denka will accelerate Icon Genetics’ new business and product development programs to address public health challenges, including the development of vaccines against the highly contagious norovirus, for which no vaccine or specific therapy currently exists.
Overview of Icon Genetics
|(1) Name||Icon Genetics GmbH|
|(2) Location||Halle, Sachsen-Anhalt, Germany|
|(3) Position and name of director||CEO, Kazuyuki Hiruta|
|(4) Line of business||Research and development, trusted research and service provision of biopharmaceuticals|
|(5) Capital||25,000 Euro|
|(7) Shareholder composition||Denka Company Limited: 100%|